{"product_id":"vbshilpa-pestle-analysis","title":"Shilpa Medicare PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Competitive Advantage Starts with This Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGain a competitive edge with our PESTLE Analysis of Shilpa Medicare—concise, current, and focused on the political, economic, social, technological, legal, and environmental forces shaping its outlook; buy the full report to access actionable insights, editable charts, and strategic recommendations tailored for investors and executives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Incentives for Pharmaceutical Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Indian government’s PLI schemes allocated about INR 69.3 billion for bulk drug and API incentives through 2024, supporting import substitution; Shilpa Medicare stands to gain from these funds as it expands API capabilities.\u003c\/p\u003e\n\u003cp\u003ePolicy focus on self-reliance has accelerated approvals and infrastructure grants, lowering capital costs for manufacturers; Shilpa’s recent capex plans align with this framework. \u003c\/p\u003e\n\u003cp\u003eAccess to PLI and related schemes facilitates scaling of oncology and non-oncology production, improving Shilpa’s competitiveness in domestic and export markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Supply Chain Diversification\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOngoing geopolitical tensions and China Plus One have boosted India’s share of global pharma manufacturing to about 3.5% in 2024 from ~2.8% in 2019, positioning Shilpa Medicare as a preferred partner for Western firms seeking diversification.\u003c\/p\u003e\n\u003cp\u003eWestern governments have rolled out incentives and procurement policies—e.g., US CHIPS-like proposals for pharma security and EU funding—prompting accelerated reshoring and supplier diversification.\u003c\/p\u003e\n\u003cp\u003eThe shift enhances Shilpa’s CRAMS prospects: the global contract manufacturing market reached ~$120bn in 2024, with India’s CRAMS exports growing ~15% YoY, increasing demand for reliable alternatives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Regulatory Harmonization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical moves to align Indian standards with USFDA and EMA are vital for Shilpa Medicare’s export-focused model; India-US pharma regulatory engagement increased inspections and cooperation, aiding Indian exports that reached $24.4bn in 2024. Government-led mutual recognition talks and reduced trade barriers—part of bilateral dialogues accounting for 15–20% faster approval pathways in pilot programs—shorten audit timelines. Such stability and cooperation accelerate Shilpa’s market entry for complex generics into high-value regulated markets, impacting time-to-revenue and margin realization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug Pricing Control Policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolitical pressure to improve affordability has prompted frequent revisions to Indias NLEM and price-control rules; since 2023, over 150 medicines were reviewed and ceiling prices reduced by up to 40% in select categories, tightening margins for manufacturers of oncology and chronic-disease drugs.\u003c\/p\u003e\n\u003cp\u003eThese measures aim to benefit patients but can cut gross margins by an estimated 5–12% for affected SKUs, pressuring Shilpa Medicare’s domestic profitability on essential products.\u003c\/p\u003e\n\u003cp\u003eShilpa must balance compliance with domestic pricing caps while sustaining global revenues from high-value specialty and biosimilar portfolios that contributed roughly 35% of FY2024 export sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFrequent NLEM updates (150+ since 2023) reduce ceiling prices up to 40%\u003c\/li\u003e\n\u003cli\u003eEstimated 5–12% margin hit on controlled essential drugs\u003c\/li\u003e\n\u003cli\u003e35% of FY2024 export sales from specialty\/biosimilars support global profitability\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Infrastructure Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIncreased government spending—India budgeted about INR 86,000 crore for health (2024–25) and expanded Ayushman Bharat coverage—broadens Shilpa Medicare’s addressable market for APIs and finished dosages.\u003c\/p\u003e\n\u003cp\u003ePolitical focus on cancer care, including 75+ upgraded oncology centers under recent schemes, boosts domestic demand for Shilpa’s oncology portfolio.\u003c\/p\u003e\n\u003cp\u003eLong-term policy commitments support steady revenue visibility as public procurement and hospital capex rise.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eINR 86,000 crore health budget (2024–25) expands patient base\u003c\/li\u003e\n\u003cli\u003e75+ oncology center upgrades increase oncology demand\u003c\/li\u003e\n\u003cli\u003eStronger public procurement supports API and FDF sales\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolicy tailwinds boost Shilpa’s export scale; NLEM price cuts could trim margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGovernment PLI\/API incentives (~INR 69.3bn through 2024), INR 86,000 crore health budget (2024–25), 75+ upgraded oncology centers, India pharma export USD 24.4bn (2024), CRAMS market ~$120bn (2024) and India manufacturing share 3.5% (2024) improve Shilpa’s scale and export access; NLEM revisions (150+ since 2023) cutting ceilings up to 40% may trim margins 5–12% on affected SKUs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePLI\/API funds\u003c\/td\u003e\n\u003ctd\u003eINR 69.3bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealth budget\u003c\/td\u003e\n\u003ctd\u003eINR 86,000cr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma exports\u003c\/td\u003e\n\u003ctd\u003eUSD 24.4bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRAMS market\u003c\/td\u003e\n\u003ctd\u003e~USD 120bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNLEM reviews\u003c\/td\u003e\n\u003ctd\u003e150+ (since 2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Shilpa Medicare across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-backed trends and forward-looking insights to inform strategy, risk mitigation, and investor-facing materials, tailored for executives, consultants, and entrepreneurs operating in the company’s industry and region.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, visually segmented PESTLE summary for Shilpa Medicare that streamlines external risk review and market positioning discussions during meetings or presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Healthcare Expenditure Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRising global healthcare spending—projected at $11.9 trillion in 2024 and growing ~5% annually—drives pharma demand in developed and emerging markets; ageing populations and chronic disease care raise demand for affordable therapies.\u003c\/p\u003e\n\u003cp\u003eIncreased public and private budgets boost demand for generics and complex dosages; oncology drug spend rose ~8% in 2023 to over $200 billion, favoring cost-effective alternatives.\u003c\/p\u003e\n\u003cp\u003eShilpa Medicare, with a strong biosimilars and oncology portfolio, is positioned to capture share by offering lower-cost substitutes to high-priced branded cancer therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Exchange Rate Fluctuations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs a major exporter to the US and Europe, Shilpa Medicare’s revenues are highly sensitive to INR\/USD and INR\/EUR swings; INR depreciated ~9% vs USD in 2022–2023 and was volatile around 82–83 in 2024, affecting dollar realizations. A weaker rupee can boost export competitiveness but raised imported API and equipment costs by 10–20% in recent years. Effective hedging (forwards\/options) and macro stability are essential to protect margins and cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary Pressures on Input Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInflation in 2024 pushed Indian WPI inflation to 5.2% year-on-year in Dec 2024, raising costs for APIs, energy and logistics and squeezing Shilpa Medicare’s margins in a price-sensitive generic market where pricing power is limited.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrowth of the Biosimilars Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe global biosimilars market, valued at about USD 18.9 billion in 2024 and projected to reach USD ~45 billion by 2030, shifts spending from costly biologics to cost-effective alternatives, creating a major economic opportunity.\u003c\/p\u003e\n\u003cp\u003eShilpa Medicare’s R\u0026amp;D investments in biosimilars align with imminent patent cliffs for top biologics, positioning it to capture higher-margin sales than traditional generics and lift revenue.\u003c\/p\u003e\n\u003cp\u003eWith payers targeting 20–40% savings versus originators, biosimilars can drive volume growth and improved profitability for Shilpa.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal market ~USD 18.9B (2024); CAGR ~14% to 2030\u003c\/li\u003e\n\u003cli\u003ePotential payer savings 20–40%\u003c\/li\u003e\n\u003cli\u003eHigher margins than small-molecule generics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rate Environment and Capex\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe prevailing interest rate environment influences Shilpa Medicare’s borrowing cost for capital-intensive expansions; India’s corporate bond yields rose to ~8.2% in 2024, raising debt service on new projects.\u003c\/p\u003e\n\u003cp\u003eHigh rates increase financing costs and can delay investments in new manufacturing or R\u0026amp;D, squeezing free cash flow; Shilpa’s net debt\/EBITDA was ~0.9x in FY2024, limiting leverage headroom.\u003c\/p\u003e\n\u003cp\u003eConversely, stable or falling rates support aggressive expansion and modernization of injectable and oral solids lines by lowering capex financing costs and improving project IRRs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 corporate yields ~8.2%\u003c\/li\u003e\n\u003cli\u003eShilpa net debt\/EBITDA ~0.9x (FY2024)\u003c\/li\u003e\n\u003cli\u003eHigh rates = higher debt service, potential delays\u003c\/li\u003e\n\u003cli\u003eLower\/stable rates = faster capex, better IRRs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eShilpa poised in a $11.9T healthcare market as biosimilars surge 14% CAGR\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGlobal healthcare spend ~USD 11.9T (2024); biosimilars market USD 18.9B (2024), CAGR ~14% to 2030; oncology spend \u0026gt;USD 200B (2023). INR ~82–83\/USD (2024) after ~9% 2022–23 depreciation; WPI inflation 5.2% Dec 2024; India corporate yields ~8.2% (2024); Shilpa net debt\/EBITDA ~0.9x (FY2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal healthcare spend\u003c\/td\u003e\n\u003ctd\u003eUSD 11.9T\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosimilars market\u003c\/td\u003e\n\u003ctd\u003eUSD 18.9B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eINR\/USD\u003c\/td\u003e\n\u003ctd\u003e~82–83\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWPI inflation (Dec)\u003c\/td\u003e\n\u003ctd\u003e5.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCorp bond yields\u003c\/td\u003e\n\u003ctd\u003e~8.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShilpa net debt\/EBITDA\u003c\/td\u003e\n\u003ctd\u003e~0.9x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eShilpa Medicare PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Shilpa Medicare PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751721775481,"sku":"vbshilpa-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/vbshilpa-pestle-analysis.png?v=1772234305","url":"https:\/\/matrixbcg.com\/products\/vbshilpa-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}